Published in Cardiovascular Business Week, February 23rd, 2010
"Thus, inhibiting the RAS with either an ARB or an ACE...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.